<?xml version="1.0" encoding="UTF-8"?>
<p id="p0365">Furthermore, a clinical trial started on March 5 (NCT04308317), planned to combine the use of the tetrandrine (60 mg once a day), in tablets form, with the standard treatment of mild and severe neo-coronary pneumonia. The aim is the slowing down the progress of the disease and therefore the improvement of patients’ prognosis. All the information on these ongoing efforts is crosslinked with our collection in 
 <xref rid="appsec1" ref-type="sec">Table S1</xref>.
</p>
